The leukocyte specific protein 1 or LSP1 is a multi functional protein involved in such divers biological processes as the regulation of neutrophil motility, chemotaxis, adhesion and membrane immunoglobulin M (mIgM) mediated apoptosis of B-lymphocytes. The 330-aminoacid mouse LSP1 protein contains a high-affinity F-actin binding site and in intact cells localizes to the F-actin filament containing cytoskeleton. Here we use a high-speed F-actin co sedimentation assay and transfection experiments in the LSP1 À T-lymphoma cell line BW5147 to show that LSP1 interacts with F-actin and the cytoskeleton through residues downstream of amino acid residue 230. We then designed a novel cell-free cytoskeleton binding assay in which a set of GST -LSP1 fusion proteins are allowed to bind to the cytoskeleton in NP-40 soluble lysates of BW5147 cells and are recovered in the low-speed detergent insoluble pellet. Using this assay the cytoskeleton binding site of mouse LSP1 maps to the 300 -330 interval. These results will allow the design of LSP1 mutants that do not bind to the cytoskeleton to determine the importance of LSP1 cytoskeleton binding for the diverse functions of LSP1. D
Introduction
The cytoskeletal protein leukocyte specific protein 1 (LSP1) is involved in the regulation of neutrophil motility in vitro and in vivo and in the regulation of neutrophil adhesion to the matrix protein fibrinogen [1] [2] [3] [4] . LSP1 is expressed in lymphocytes, neutrophils and macrophages but not in other hematopoietic or non-hematopoietic cells [5 -8] . Mouse LSP1 protein contains 330 amino acids and shares significant sequence homology with the 339 amino acid human LSP1 protein, also known as WP34 or pp52 [9 -11] . Mouse and human LSP1 bind to F-actin in vitro and to F-actin filaments in intact cells [4, 9, 12, 13] . Mouse LSP1 binds to F-actin and to the cytoskeleton through its COOHterminal residues 179 -330 [9] . The COOH-terminal residues 180 -339 of human LSP1 contain several F-actin binding domains, two designated CI and CII that show homology to sequences found in the F-actin binding protein caldesmon and two designated VI and VII with homology to villin [12] . Each of the four F-actin binding domains in human LSP1 contributes to F-actin binding in vitro and, when expressed in Sf9 insect cells, all F-actin binding domains need to be present for LSP1 to function as an Factin bundling protein in intact cells [12, 14] . Since the bundling activity of human LSP1 depends on the presence of multiple F-actin binding sites, the above experiments did not directly address which sequences in LSP1 are sufficient for binding to F-actin filaments. To address this question, we mapped the F-actin and cytoskeletal binding site of mouse LSP1 using several approaches. First, using truncated LSP1 proteins in an in vitro high-speed co-sedimentation assay or expressed in vivo in the LSP1
À T-lymphoma cell line BW5147, we showed that the F-actin binding site and the cytoskeletal binding site of mouse LSP1 are located downstream of LSP1 residue 230. We then designed an in vitro cell-free cytoskeleton binding assay and determined that the cytoskeleton binding site of LSP1 is located between residues 300 and 330. These residues contain the mouse LSP1 sequences homologous to the human VI and VII domains. The mouse sequences homologous to regions CI and CII in human LSP1 do not contribute to F-actin binding or to cytoskeletal binding of mouse LSP1.
Materials and methods

Cells and media
The LSP1
À T-lymphoma cell line BW5147 was grown in complete RPMI-1640 tissue culture medium supplemented with 10% FCS as described [9] .
Antisera and Western blot analysis
Western blot analysis was performed on Immobilon membranes (Millipore Corp., Bedford, MA). Proteins were analyzed with anti-LSP1 serum [15] , anti-actin monoclonal antibodies [9] or an anti-serum that recognizes glutathione-S-transferase (GST) and visualized using the ECL detection kit (Amersham BioSciences, Oakville, Ontario).
Construction of recombinant LSP1 mutant proteins
Eukaryotic expression vectors encoding LSP1-CAT fusion proteins containing LSP1 residues 1 -330, 1 -178, 1 -230, 1 -178/231 -330 or 179 -330 of LSP1 were constructed as described in Ref. [9] . Constructs were then stably transfected into BW5147 cells by electroporation (450 V, 150 AF) using the BioRad electroporator system. The GST -LSP1 fusion proteins containing residues 1 -300, 1 -178, 179-330, 179 -230, 231 -330, 270-330, 285 -330, 300 -330 and 231 -300 were constructed using PCR with the mouse LSP1 cDNA as template. The DNA fragments were subcloned into the pBluescript II KS (+) vector (Stratagene, La Jolla, CA) for sequencing and then transferred into the pGEX-4T-2 vector (Amersham Biosciences). All DNA fragments were expressed as GST -LSP1 fusion proteins in E. coli BL21(DE3) cells. Recombinant proteins were purified according to standard procedures and the concentration of each recombinant protein was calculated by using the optical density measurement at 280 and 320 nm, the extinction coefficients of tyrosine (1390 M ) and tryptophan (5800 M À 1 cm À 1 ) and the number of tyrosine and tryptophan residues present in each GST -LSP1 fusion protein.
In vitro F-actin binding assay and Scatchard analyses
The high-speed co-sedimentation F-actin binding assay was performed exactly as described previously using 5 Ag of GST or GST -LSP1 fusion proteins and 4 AM rabbit skeletal muscle actin in a total volume of 100 Al [9] . To control for the solubility of the GST -LSP1 proteins, the assays were also done without added actin. The amount of GST or GST -LSP1 fusion protein in the high-speed pellet was determined as a fraction of the amount of input protein by densitometry using a standard curve constructed of a series of twofold dilutions of the input protein as described [9] . For Scatchard analyses, a constant amount of actin was mixed with varying amounts of GST fusion protein and polymerized. The amount of polymerized actin in the pellet was independent of the amount of added GST fusion protein and was between 0.8 and 1.0 Amol.
In vivo cytoskeletal binding assay
BW5147 cells and stable transfectants expressing LSP1 -CAT fusion proteins were lysed by incubation with detergent and the detergent insoluble cytoskeletal material was purified through a sucrose cushion as described [9, 16] . At least three independent assays were done for each BW5147 transfectant and the results are presented as the average extent of cytoskeletal binding F 1 S.D.
Preparation of a nuclear fraction by nitrogen cavitation
Cells (5 Â 10 7 ) of the BW5147 transfectant BW20 were washed three times in cold PBS. Cells were resuspended in lysis buffer without NP-40 at a concentration of 1 Â 10 7 cells/ml and disrupted using a Parr Cell Disruption Bomb #4639 filled with N 2 gas at a pressure of 700 psi. The entire crude lysate (5 ml) was layered on 2 ml of a 0.88M sucrose cushion and centrifuged at 1300 Â g for 8 min. Lysis buffer containing 0.5% NP-40 was added to the pellet and centrifuged as above. The resulting nuclear fraction was resuspended in Laemmli sample buffer and immersed in boiling water for 5 min. In parallel, cells were also lysed with NP-40 and centrifuged as above to generate a NP-40 insoluble pellet. A total cell lysate was generated by lysis of cells in SDS-containing sample buffer. All samples were immersed in boiling water for 3 min after the addition of Laemmli sample buffer. To check for histone content, aliquots of the NP-40 insoluble pellet and the nuclear fractions were separated on a SDS-12.5% polyacrylamide gel and stained with Coomassie brilliant blue.
2.7. Cell-free cytoskeletal binding assay BW5147 cells were lysed as described for the in vivo cytoskeleton binding assay at a cell density of 4 Â 10 7 cells/ ml. GST -LSP1 fusion proteins (15 Al containing f 5 g of protein diluted in 50% glycerol) were added to 100 Al of BW5147 lysate and incubated on ice for 45 min. Next, two aliquots of 50 Al were collected. One aliquot was designated as the input sample and was used to prepare a calibration curve for quantitation purposes. The other aliquot was centrifuged at 14,000 Â g in a microfuge (Biofuge A, American Scientific Products) for 5 min at 4 jC to pellet the detergent-insoluble cytoskeleton. The cytoskeletal pellet was washed once with lysis buffer and then dissolved in 75
Al of Laemmli sample buffer and immersed in boiling water for 5 min. Proteins in the pellet fractions and those from the input sample were separated on SDS-12.5% PAGE and the amount of each GST -LSP1 fusion protein present in the pellet fraction was quantitated by Western blot analysis as the percentage of input GST -LSP1 fusion protein. To quantitate cytoskeletal binding, a calibration curve was used that was constructed by analyzing twofold dilutions of input protein. At least three independent assays were done for each GST -LSP1 fusion protein and the results are presented as the average percent of cytoskeletal binding F 1 S.D.
Results
Residues 231 -330 of LSP1 are sufficient for F-actin and cytoskeleton binding
Using a high-speed F-actin co-sedimentation assay, we have shown that LSP1 binds to F-actin through residues 179 -330, while residues 1 -178 do not bind to F-actin [9] . Experiments shown in Fig. 1A confirm these results in a quantitative manner. At approximately equal molar input, similar fractions of intact LSP1 residues 1 -330 (39.1%) or LSP1 residues 179 -330 (48.6%) bind to F-actin. The fraction of GST -LSP1/1 -178 in the high-speed pellet (2.6%) was not significantly different from the amount of GST protein (0.9%). To more precisely determine the LSP1 sequences involved in F-actin binding, we tested GST -LSP1 fusion proteins containing different intervals of the 179 -330 sequence. Fig. 1A shows that 30.3% of GST -LSP1/231-330 binds to F-actin, while only 0.4% of GST -LSP1/179-230 binds to F-actin. The presence of GST -LSP1/231-330 in the high speed pellet was not due to insolubility of the GST -LSP1 fusion protein in the assay buffer as no recombinant LSP1 protein was detectable in the high-speed pellet when actin was omitted from the binding assay (Fig. 1B third panel, lane 4) . Binding of LSP1 residues 231 -330 was not significantly different from the binding of either intact LSP1 residues 1 -330 or of residues 179 -330. Examples of binding assays for GST -LSP1/1 -330, GST -LSP1/231 -330 and GST -LSP1/179-230 are shown in panel B. Binding of GST -LSP1/231-330 to Factin was saturable at a molar ratio of approximately 1:1 (Fig. 1C, inset) . Scatchard analysis showed that the dissociation constant for binding of GST -LSP1/231 -330 to Factin is f 0.2 AM with an apparent stoichiometry of binding of f 0.5 mol of GST -LSP1/231 -330 per mole of F-actin. These values are very similar to those found for the dissociation constant (0.2 AM) and stoichiometry of binding (0.6) when intact LSP1 was used for binding [9] . Thus, we conclude from these results that the main F-actin binding site of mouse LSP1 is located downstream of residue 230 in the 231-330 interval. Similar to the findings for intact LSP1, we also found low-affinity binding of GST -LSP1/231 -330. However, this may reflect nonspecific binding of the fusion protein to F-actin filaments or trapping of small amounts of the fusion protein in the Factin filament pellet.
The presence of an F-actin binding domain between LSP1 residues 231 and 330 predicts that these residues are sufficient to direct LSP1 to the F-actin filaments when expressed in cells. To confirm this prediction, we expressed intact LSP1 (residues 1 -330) and a mutated form of LSP1 from which residues 179 -230 have been deleted (1 -330D179 -230) in the LSP1
À T-lymphoma cell line BW5147 cells. To ensure stable expression of LSP1 truncate we fused the LSP1 sequences to the NH 2 terminus of the bacterial CAT protein. All constructs were expressed at similar levels (A.I. Malapitan and J. Jongstra, unpublished data). Cytoskeletal binding was determined using anti-CAT antibodies to assay the amount of LSP1 -CAT fusion protein in the NP-40 insoluble pellet of BW5147 cells stably expressing the LSP1 -CAT fusion proteins. Fig. 2A shows that 30.5% of the CAT -LSP1/1 -330 fusion protein was present in the cytoskeletal pellet of BW4 cells, while a similar fraction of the LSP1 -CAT/1 -330D179 -230 (27.4%) was present in the cytoskeletal pellet of BW20 cells. 1 and 3) , indicating that in this particular experiment f 25% of the expressed CAT -LSP1/1 -330D179 -230 protein binds to the cytoskeleton. The presence of the LSP1 -CAT/1 -330D179 -230 protein in the cytoskeletal pellet of BW20 cells was not due to the presence of LSP1 residues 1 -178 or of the CAT protein since only a small fraction of these sequences was present in the cytoskeletal pellets of BW57 and BW711 cells, respectively ( Fig. 2A) . Cytoskeleton binding of the LSP1 sequence 179 -230 that are deleted from CAT -LSP1/1 -330D179 -230 was not significantly higher than that of residues 1 -178. Thus these results show that LSP1 residues 231-330 direct the binding of LSP1 to the NP-40 insoluble cytoskeletal pellet.
Since the NP-40 insoluble pellet contains the nucleus as well as F-actin filaments [17] , we needed to confirm that the CAT -LSP1/1 -330D179 -230 protein expressed in the transfected line BW20 is present in the NP-40 detergent insoluble fraction because of an association with the cytoskeleton and not because it is associated with the nucleus or is merely insoluble in the lysis buffer used. To address this, we made nuclear fractions of BW20 cells using nitrogen cavitation under conditions which disrupt the cytoskeleton but leaves the nuclear fraction intact. The yield of the nuclear fraction as determined by analyzing the histone content on Coomassie blue-stained SDS-PAGE was essentially 50% as the nuclear fraction of 8 Â 10 5 BW20 cells (panel C, lane 2) contains an amount of histones approximately equal to 4 Â 10 5 cell equivalents of the NP-40 insoluble pellet (lane 1) or of a total lysate (not shown). Lysis using nitrogen cavitation results in extensive disruption of the cytoskeleton as measured by the absence of actin in the nuclear pellet, which contains less than 1/8th the amount of actin present in the NP-40 insoluble pellet (panel D, lanes 2 and 3). Importantly, the amount of CAT -LSP1/ 1 -330D179 -230 protein in the nuclear fraction is reduced to a similar extent (panel B, lanes 4 and 5). Thus, the LSP1/ 1 -330D179 -230 protein containing the F-actin binding domain within residues 231 -330 is present in the detergent insoluble fraction of BW20 cells due to its association with the cytoskeleton and not with the nucleus or as a result of insolubility in the lysis buffer used. were lysed using 0.5% NP-40 and incubated with 5 Ag of the GST -LSP1/ 1 -330 on ice for 45 min to allow binding of the GST -LSP1 protein to the cytoskeleton present in the BW5147 NP40 lysate. After centrifugation for 5 min at 14,000 rpm, the amount of GST -LSP1/1 -330 protein present in the NP-40 insoluble cytoskeletal pellet was determined by densitometry. Fig. 3B shows that in this particular experiment 23.5% of the input GST -LSP1/1 -330 fusion protein bound to the cytoskeleton (Pel). The GST -LSP1/1 -330 protein is not insoluble in lysis buffer containing 0.5% NP-40 since no fusion protein was detected in the pellet fractions from binding assays in which the fusion protein was incubated in lysis buffer containing 0.5% NP-40 without BW5147 lysate (Cntrl). No cross-reacting band was present in the BW5147 lysate at the same level as the GST -LSP1/1 -330 fusion protein, as determined by analyzing the BW5147 lysate without addition of GST -LSP1/1-330 protein (Lys).
No significant proteolysis of the fusion protein occurs during the assay as determined by comparing the non-bound (Sup) with the input GST -LSP1/1 -330 fusion protein. Panel A shows that 24.9% of the GST -LSP1/1 -330 protein (line 1), 31.0% of GST -LSP1/179 -330 (line 3) and 28.6% of the GST -LSP1/231 -330 protein (line 5) bind to the cytoskeleton in BW5147 cell lysates, while < 0.25% of the GST -LSP1/1 -178 (line 2) and < 0.5% of the GST -LSP1/ 179 -230 protein (line 4) bind to the cytoskeleton. These results show that the cytoskeleton binding site is located between residues 231 and 330 and that the use of the cellfree binding assay or analysis of stable transfectants leads to the same conclusion.
We assayed six additional GST -LSP1 proteins. Significant binding to the cytoskeleton was detected for proteins containing LSP1 residues 270 -330 (24.7%), 285 -330 (29.0%) and 300 -330 (21.2%, lines 6 -8), but not for the GST -LSP1/1 -300 ( < 1%) and the GST -LSP1/231 -300 ( < 0.5%, lines 9 and 11) proteins. This is strong evidence that only residues in the 300-330 interval contribute to cytoskeletal binding. Analysis of the cytoskeletal binding activity of residues 179 -330, 231 -330, 270 -330, 285 -330 and 300 -330 of LSP1 by ANOVA showed that the slight variations in the extent of cytoskeletal binding were not significant ( P>0.05). Thus, we conclude that the cytoskeletal binding site of LSP1 is located between residues 300 and 330.
Discussion
Several studies have shown that LSP1 is involved in the regulation of cell motility, adhesion to extracellular matrix proteins and cell morphology. Howard et al. [3, 4] showed that overexpression of LSP1 in human neutrophils or in human melanoma cells inhibits cell motility and leads to the formation of LSP1 and F-actin containing membrane protrusions. Our lab has shown that compared to neutrophils from wild-type mice, neutrophils from Lsp1 À / À mice display increased chemotaxis towards a gradient of the chemoattractant KC and fMLP and show increased adhesion to fibrinogen but not to fibronectin [1, 2] . The F-actin and cytoskeletal binding characteristics of LSP are consistent with its role as a regulator of cell motility and adhesion as these are cytoskeleton-dependent biological processes. On the other hand, expression of the COOH-terminal LSP1 residues 179 -330 in the mouse B-lymphoma cell line W10 results in the inhibition of anti-immunoglobulin M (IgM)-induced activation of the PKC/ERK MAPkinase pathway and increases anti-IgM-induced apoptosis, which shows that LSP1 is a regulator of membrane IgM (mIgM)-induced apoptosis and that the residues critical to this apoptotic function of LSP1 reside between residues 179 and 330. In addition to binding F-actin and the cytoskeleton, LSP1 residues 179-330 also bind directly to PKChI [18] . This suggests that LSP1 targets at least a fraction of the intracellular PKChI and possibly other components of the PKC/ ERK MAPkinase pathway to a cytoskeletal location. Although cytoskeletal proteins such as Hsp25/27 [19] , gelsolin [20, 21] or DAP kinase [22] have been shown to be involved in the regulation of apoptosis, it needs to be determined whether cytoskeletal binding of LSP1 and targeting PKChI to the cytoskeleton is important for its function as a regulator of anti-IgM induced apoptosis. Using expression of LSP1 truncates or mutants that do not bind to the cytoskeleton in W10 cells may clarify this point.
The objective of the studies in this paper was to define the sequences sufficient for mouse LSP1 to bind the cytoskeleton. Previous experiments showed that mouse LSP1 binds to F-actin and to the cytoskeleton through the COOH-terminal residues 179 -330 [9] . A more detailed study on human LSP1 identified at least three and possibly four specific regions in the COOH-terminal half of human LSP1 that each individually can function as an F-actin binding site [12] , suggesting that binding of LSP1 to the F-actin filaments in intact cells involves three or four binding sites. Indeed, it was shown that all F-actin binding sites were necessary for human LSP1 to function as an Factin bundling protein [14] . However, the question of which of these F-actin binding sites in human LSP1 are sufficient for cytoskeletal binding was not addressed. Here we describe a novel cell-free cytoskeletal binding assay and use this assay to map the cytoskeletal binding site of LSP1 between residues 300 and 330. We quantitated the cytoskeletal binding activity of the recombinant LSP1 protein frag- ments after expression in intact cells or in the cell-free assay by measuring the amount of intact or truncated LSP1 protein in the NP-40 insoluble pellet fraction. We now have performed two appropriate control experiments that show that the intact endogenous LSP1 protein expressed in the Blymphoma cell line BAL-17 [16] or the fusion protein containing LSP1 residues 1 -178/231 -330 expressed in the transfectant BW20 (this paper) are present in the NP-40 insoluble pellet because of an association with insoluble cytoskeletal elements and not because of a nuclear location or because of insolubility in the lysis buffer. Thus we conclude that the data in Fig. 2 represent the extent of cytoskeletal binding of the various LSP1 fusion proteins assayed, rather than their binding to the nucleus. We tested the validity of the cell-free binding assay by comparing the results obtained in that assay with those using the in vivo expressed proteins. Using intact LSP1 and four LSP1 fragments (1-178, 179-230, 179-330 and 231 -330), both methods mapped the cytoskeleton binding site to the same region downstream of LSP1 residue 230, which suggests strongly that the results obtained using the cell-free assay are valid measurements of cytoskeleton binding. The cellfree assay is, however, much less time-consuming as it is not necessary to establish stable transfectants for each mutated LSP1 protein assayed and therefore should permit the use of a larger collection of LSP1 mutants leading to a more accurate mapping of the LSP1 cytoskeletal binding domains. Indeed, we used an additional six LSP1 truncates to map the cytoskeleton binding site to the LSP1 residues 300 -330.
Our results using mouse LSP1 differ from those described for human LSP1 [12, 14] . The only F-actin and cytoskeletal binding sites in mouse LSP1 are present downstream of residue 300, while the results of mapping experiments using human LSP1 would predict the presence of two F-actin binding domains in mouse LSP1 upstream of residue 300, between residues 196-228 (homologous to the human CI domain) and residues 251 -267 (homologous to the human CII domain). However, it is unlikely that the mouse sequence 196 -228 contributes to F-actin binding of LSP1 in vitro since the sequence 179 -230 does not bind to Factin as shown in Fig. 1 . Scatchard analyses of the binding data (Fig. 1C) also support the conclusion that the main Factin binding activity is located in the 231 -330 region. We have previously calculated the K d of binding of rLSP1 to Factin as approximately 0.2 AM and Scatchard analysis of the binding data of the GST -LSP1/231 -330 is in good agreement with the measurements using intact LSP1, both giving a K d of approximately 0.2 AM and a final stoichiometry of binding of approximately 0.6 mol of LSP1 for each mole of actin. Thus there is good evidence that LSP1 interacts with F-actin only through sequences downstream of residue 231. Similarly, we have no evidence that either residues 196 -228 or residues 251 -267 of mouse LSP1 contribute to the cytoskeletal binding of LSP1, since neither GST -LSP1/ 179 -230 nor GST -LSP1/231 -300 bind to the cytoskeleton (Figs. 2 and 3) . The reason why we were not able to demonstrate the presence of functional CI and CII domains in mouse LSP1 is not clear, but does not seem to be related to differences in binding assays or source of recombinant protein. Both mouse and human CI domain-containing truncates were assayed for F-actin binding using the highspeed co-precipitation assay using bacterially derived recombinant proteins [12] . Comparison of the mouse and human sequences of the CI and CII domains, however, showed six differences between mouse and human CI domains and four differences between human and mouse CII domains. Hence, the mouse CI and CII domains may not be functional because of differences in residues critical for F-actin binding. In agreement with the results obtained with human LSP1, we found that mouse LSP1 residues 300 -330 bind to F-actin. These residues contain the sequences 307-310 and 318 -321 that are identical to the human VI and VII sequences, respectively. The VI and VII sequences are short basic sequence motifs (KRYK and KYEK, respectively) that resemble an F-actin binding motif (KKEK) in the headpiece of villin. Mutation of one or two basic residues in VI or VII significantly inhibited binding of human LSP1 for F-actin, indicating that the VI and VII motifs contribute independently to the F-actin binding characteristics of human LSP1 [12] . We have not made single or double point mutations in the mouse VI or VII sequences and thus our results do not allow us to conclude whether these specific sequences are involved in F-actin and cytoskeletal binding. However, we showed that only 1.9% of a GST fusion protein containing LSP1 residues 231 -320 that eliminates the C-terminal K residue of the VII domain binds to the cytoskeleton in the cell-free assay (Fig. 3A, line 10) , suggesting that in agreement with the mutation studies of Howard et al., changes in the basic residues of the VII domain significantly inhibit the F-actin binding characteristics of LSP1.
